Recent Chart Audit of Multiple Sclerosis Patients Recently Switched to a New Disease-Modifying Therapy Shines Spotlight on Gains by Genentech’s Ocrevus in the Secondary Progressive and Primary Progressive Patient Segments
The oral disease-modifying therapy class remains the switch share leader although a shift into the first-line position and recent branded and generic launches has consistently chipped away at class share year-over-year, according to a new independent audit from Spherix Global Insights Download Report Overview EXTON, Pa., April 25, 2018 /PRNewswire/ — With the highest self-reported […]
Uptake of Merck KGaA’s Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals
Early launch of Roche’s Ocrevus has surpassed Mavenclad due to first-in-market primary progressive multiple sclerosis label and broad access through compassionate use programs, although transitioning to country-level health plans may slow future momentum, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., March 27, 2018 /PRNewswire/ — With an additional […]
Genentech’s Ocrevus Begins to Move the Needle on the Treatment Rate for Primary Progressive Multiple Sclerosis but May Not Be the Only Disease-Modifying Therapy in Play
Irrespective of Celgene’s recent receipt of a refusal-to-file letter for ozanimod, neurologists are eagerly awaiting a secondary progressive multiple sclerosis indication for Novartis’ siponimod, but are more divided on the value EMD Serono’s Mavenclad will bring to their practices, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., March 13, […]
Heavy-hitting MS Therapies Now Being Used Sooner for Some Patients
From: Multiple Sclerosis News Today By: Ed Tobias However, a recent audit of patients and neurologists by Spherix Global Insights, a business intelligence and market research company, reports an apparent change in attitude about cost…(read more).
Use of Monoclonal Antibody Disease-Modifying Therapies on the Rise in Multiple Sclerosis, Fueled Largely by the Introduction of Genentech’s Ocrevus
According to the most recent quarterly update from Spherix Global Insights, multiple sclerosis-focused neurologists report increased use of monoclonal antibody disease-modifying therapies and a recent chart audit of over 500 patients on monoclonal antibody disease-modifying therapy highlights important characteristics for patients being selected for this class of disease-modifying therapies Download Report Overview EXTON, Pa., January […]
With Ocrevus Uptake in Primary Progressive Multiple Sclerosis a Relative Lock, Genentech and US Neurologists are Increasingly Focused on Ocrevus Positioning in Relapsing Forms of Multiple Sclerosis
Swift uptake of Mylan’s generic glatiramer acetate 20mg and 40mg is being driven by perceptions of preferential payer coverage although a dispensed-as-written strategy for Teva’s Copaxone may be limiting greater conversion, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., December 7, 2017 /PRNewswire/ — Seven months post-launch, the clear […]
Early Adopters in Germany and the United Kingdom Are Prescribing Merck KGaA’s Mavenclad as First-Line Induction Therapy for the Treatment of Multiple Sclerosis
European neurologists predict substantial uptake of Roche’s Ocrevus among primary progressive multiple sclerosis patients driven by favorable market access status and an absence of on-label competition, according to a new EU5 report from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 21, 2017 /PRNewswire/ — The multiple sclerosis (MS) market in the EU is […]
Advanced Practice Providers Treat Significantly More of their Multiple Sclerosis Patients with Monoclonal Antibody Disease-Modifying Therapies Compared to Neurologists in the US
Market access restrictions for these high efficacy therapies may be hindering their ability to optimally treat their clinically complex, relapsing patients, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 15, 2017 /PRNewswire/ — Advanced practice providers (APPs), including nurse practitioners and physician assistants, play an important role as […]
FDA Approval of Mylan’s Glatiramer Acetate Will Turn the Payer Pressure On for Teva’s Copaxone and Sandoz’s Glatopa
While Copaxone brand loyalists and therapeutic equivalence concerns remain, the preference for three-times-weekly dosing will diminish reluctance to initiate generics, according to the most recent quarterly update by Spherix Global Insights Download Report Overview EXTON, Pa., Oct. 4, 2017 /PRNewswire/ — With the FDA approval and imminent shipping of Mylan’s generic glatiramer acetate (GA 20mg […]
First-in-Class PPMS Indication Fueling Much of the Adoption of Genentech’s Ocrevus, but Insurance Coverage Issues Could be a Looming Stumbling Block
As previously predicted, Ocrevus trial and share has increased significantly, positioning the new market entrant as second only to Biogen’s Tysabri in the mAb DMT class, according to the most recent quarterly update by Spherix Global Insights Download Report Overview EXTON, Pa., Sept. 19, 2017 /PRNewswire/ — Four months post-launch, keeping pace with neurologists’ previous […]
